We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Proposed low-dose doxycycline to suppress micro- and nanoplastic-induced inflammation
Summary
Researchers propose that low-dose doxycycline could help suppress inflammation triggered by micro- and nanoplastic accumulation in human tissues. The study notes that these particles have been detected in blood, placenta, lung, and testes, where they trigger pro-inflammatory signaling pathways. Since tissue clearance of microplastics is insufficient, the authors suggest that targeting the downstream inflammatory response with existing medications warrants further investigation.
Micro- and nanoplastics (MNPs) have been detected in human blood, placenta, lung, and testes. Across in vitro and animal models, MNPs trigger pro-inflammatory signaling (ROS, NF-κB/MAPK, NLRP3) and matrix remodeling. Because tissue clearance is insufficient and removal methods such as apheresis target only circulating particles, interventions that blunt downstream inflammatory pathways are critical. Tetracyclines, including doxycycline and minocycline, act on these same pathways by lowering ROS, suppressing NF-κB and MAPK activity, blocking NLRP3 activation, and inhibiting matrix metalloproteinases (MMPs). Evidence for tetracyclines spans liver, gut, lung, kidney, and brain, indicating broad and consistent mechanistic overlap rather than isolated effects. Doxycycline is safely used long-term at low (sub-antimicrobial) doses (e.g., rosacea, periodontitis) with minimal evidence of resistance selection or microbiota disruption, making it a plausible candidate to blunt MNP-induced inflammation. Despite the convergence, no study has directly evaluated low-dose tetracyclines as potential countermeasures to MNP toxicity. This review proposes a testable hypothesis to evaluate low-dose doxycycline as an intervention against MNP-induced inflammation in high-exposure populations.